携带高风险细胞遗传学异常(HRCAs)的新诊断多发性骨髓瘤(NDMM)患者,预后较差,这些患者通常对传统治疗反应不佳,且疾病进展迅速。 2024年4月,《Blood Cancer Journal》发表了一篇题为《Daratumumab-based quadruplet therapy for transplant-eli...
此外新型药物治疗也被认为是EMD出现的风险因素,但支持这一观点的数据尚不明确。 近日《Blood Cancer Journal》杂志发表了一篇综述,它基于在pubmed的系统性文献检索,共纳入29篇文献,重点关注于血源性髓外病变(EMD,包括CNS EMD),涵盖的领域包...
参考文献 Shebli Atrash ,et la.Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.Blood Cancer J . 2022 Mar 23;12(3):46. doi: 10.1038/s41408-022-00638-0....
基于已确定的额外细胞遗传学风险因素和对多打击疾病预后意义的更深入理解,来自梅奥诊所的Shaji K. Kumar教授牵头一项研究,旨在评估NDMM患者一个的新的简化叠加分期系统,即Mayo Additive Staging System(MASS)。文章发表于Blood Cancer Journal杂志。 在研究中,作者纳入了梅奥诊所2004-2019年间,所有存在FISH细胞遗传学结果...
Myeloma cells spread through the bone marrow. They can damage your bones and crowd out healthy blood cells. These cells also make antibodies that can't fight off infections. This cancer is often called multiple myeloma because it's found in many parts of your bone marrow. ...
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables inclu
MULTIPLE MYELOMA Predominantly seen in the elderly,multiple myelomais becoming more common in Singapore due to the ageing population. This type of cancer — characterised by genetic mutations that accumulate over time — can significantly impact various organs, particula...
The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory
New Drug Shows Potential for Blood Cancer; Multiple Myeloma Patients Saw Survival Gains When Elotuzumab Was Added to TreatmentThompson, Dennis
Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.Davies currently serves as director of the clinical myeloma program at Perlmutter Cancer Center and professo